Back

Do medical marijuana laws increase prescription stimulant use?

Alexander, G.; Cavanah, L. R.; Goldhirsh, J. L.; Huey, L. Y.; Piper, B. J.

2023-01-30 pharmacology and therapeutics
10.1101/2023.01.29.23285169 medRxiv
Show abstract

BackgroundChronic cannabis use can present with cognitive impairments that resemble ADHD. Our objective was to determine if medical cannabis (MC) legalization increased prescription stimulant distribution. MethodsWe extracted distribution of methylphenidate, amphetamine, and lisdexamfetamine from the Drug Enforcement Administrations comprehensive database for 2006 to 2021 and compared the three-year population-corrected slopes of stimulant distribution before and after MC program implementation. ResultsWe found a very large main effect of time (p[≤]0.001), but, contrary to the hypothesis not states MC sales status, on slopes of distribution (p=0.391). There was a significant and large interaction effect of time and MC sales status on slopes of distribution (p[≤]0.001). DiscussionThese findings suggest that medical cannabis program legalization may have contributed to some states having more rapid increases in Schedule II stimulant distribution rates over time.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nicotine and Tobacco Research
◐ 13 papers in training set
Top 0.1%
19.4%
Similar papers in this journal
2
PLOS ONE
● 5266 papers in training set
Top 17%
10.3%
Similar papers in this journal
3
Frontiers in Pharmacology
○ 111 papers in training set
Top 0.2%
7.1%
Similar papers in this journal
4
Psychopharmacology
○ 69 papers in training set
Top 0.2%
5.8%
Similar papers in this journal
5
International Journal of Neuropsychopharmacology
◐ 14 papers in training set
Top 0.1%
5.1%
Similar papers in this journal
6
Drug and Alcohol Dependence
○ 41 papers in training set
Top 0.2%
4.2%
50% of probability mass above
7
Frontiers in Psychiatry
○ 87 papers in training set
Top 0.6%
3.4%
8
European Child & Adolescent Psychiatry
○ 15 papers in training set
Top 0.1%
3.3%
9
eLife
● 5828 papers in training set
Top 38%
2.9%
10
PeerJ
◐ 308 papers in training set
Top 3%
2.6%
11
Scientific Reports
○ 3612 papers in training set
Top 44%
2.2%
12
Schizophrenia
○ 21 papers in training set
Top 0.2%
2.2%
13
Psychiatry Research: Neuroimaging
○ 18 papers in training set
Top 0.1%
1.8%
14
NeuroImage: Clinical
○ 144 papers in training set
Top 2%
1.4%
15
Pharmacology Research & Perspectives
○ 11 papers in training set
Top 0.2%
1.4%
16
European Neuropsychopharmacology
○ 20 papers in training set
Top 0.2%
1.4%
17
International Journal of Drug Policy
○ 12 papers in training set
Top 0.2%
1.4%
18
Genes
○ 144 papers in training set
Top 2%
1.2%
19
Journal of Affective Disorders
○ 92 papers in training set
Top 1%
1.2%
20
British Journal of Clinical Pharmacology
○ 21 papers in training set
Top 0.3%
1.2%
21
Alcoholism: Clinical and Experimental Research
○ 14 papers in training set
Top 0.2%
0.9%
22
NeuroImage
○ 903 papers in training set
Top 6%
0.9%
23
Addiction Biology
○ 51 papers in training set
Top 0.6%
0.9%
24
Progress in Neuro-Psychopharmacology and Biological Psychiatry
○ 48 papers in training set
Top 1%
0.6%
25
Psychological Medicine
◐ 88 papers in training set
Top 2%
0.6%
26
American Journal of Preventive Medicine
○ 11 papers in training set
Top 0.3%
0.6%
27
American Journal of Psychiatry
● 24 papers in training set
Top 0.7%
0.6%
28
Addiction
○ 30 papers in training set
Top 0.5%
0.5%
29
JMIRx Med
◐ 32 papers in training set
Top 3%
0.5%
30
Molecular Pharmacology
○ 17 papers in training set
Top 0.3%
0.5%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.